SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-16-710743
Filing Date
2016-09-15
Accepted
2016-09-15 13:37:03
Documents
3
Group Members
DAN ORENDEXCEL PHARMA TECHNOLOGIES LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d258213dsc13da.htm SC 13D/A 61741
2 EX-99.2 d258213dex992.htm EX-99.2 70702
3 EX-99.3 d258213dex993.htm EX-99.3 70485
  Complete submission text file 0001193125-16-710743.txt   204407
Mailing Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9
Business Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9 416-703-2449
Cynapsus Therapeutics Inc. (Subject) CIK: 0001532079 (see all company filings)

IRS No.: 981226819 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88902 | Film No.: 161886836
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1 DEXCEL STREET OR AKIVA L3 30600000
Business Address 1 DEXCEL STREET OR AKIVA L3 30600000 972-4-636404
Dexxon Holdings Ltd. (Filed by) CIK: 0001636684 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D/A